Emcure Pharma Q1 FY27 Results: Revenue Rs 2,580 Cr, PAT Rs 292 Cr and Key Highlights

Emcure Pharma Q1 FY27 results were announced on August 6, 2026, on a Consolidated basis. Emcure Pharma Q1 FY27 results show revenue grew +22.85% year-on-year to Rs 2,580 Cr from Rs 2,100 Cr in Q1 FY26, reflecting sustained demand in the Pharmaceuticals segment. The broader Nifty Pharma index also reflected mixed sentiment during the quarter.

Operating profit improved +33.30% YoY to Rs 422 Cr from Rs 317 Cr, indicating stronger operational efficiency. PAT rose +36.17% YoY to Rs 292.00 Cr from Rs 214.00 Cr in Q1 FY26. The quarterly numbers offer a detailed picture of how the company is navigating the current pharmaceuticals environment.

Click Here – Get Free Investment Predictions

Emcure Pharma Q1 FY27 Financial Highlights

Metric	Q1 FY27 (Rs Cr)	Q1 FY26 (Rs Cr)	YoY Change
Emcure Pharma Revenue	2,580	2,100	+22.85%
Operating Profit	422	317	+33.30%
Net Profit (PAT)	292	214	+36.17%
Reporting Basis	Consolidated

Emcure Pharma Q1 FY27 Performance Analysis

Check the Univest Screener for Live Data on This Stock

Emcure Pharma Q1 FY27 results reflect healthy fundamentals across key financial parameters. Revenue momentum continued on a strong footing with the top line reaching Rs 2,580 Cr for the April to June 2026 quarter.

Operating profit stood at Rs 422 Cr, expanding +33.30% YoY. Margin improvement signals better cost absorption and product mix optimisation.

PAT of Rs 292 Cr marks a +36.17% year-on-year improvement. Investors monitoring Emcure Pharma Q1 FY27 results will note this as a key milestone for FY27 tracking.

Key Business Factors in Emcure Pharma Q1 FY27 Results

Revenue Growth Momentum in the Pharmaceuticals Segment

Emcure Pharma Q1 FY27 results demonstrate consistent top-line expansion, with revenue rising +22.85% YoY to Rs 2,580 Cr. Volume-led growth and pricing discipline in key markets drove the uptick.

Operating Margin Expansion Signals Efficiency Gains

Operating profit in Emcure Pharma Q1 FY27 results rose +33.30% YoY to Rs 422 Cr. This reflects tighter cost control, better product mix, and operating leverage as the company scales volumes in core business lines.

PAT Performance and Profitability Trend

Net profit in Emcure Pharma Q1 FY27 results stood at Rs 292 Cr (+36.17% YoY). The sustained PAT growth reflects the company's improving financial profile.

Dividend Details

No dividend was announced along with Emcure Pharma Q1 FY27 results. The company is likely retaining earnings for reinvestment into growth capex and working capital requirements.

FY27 Outlook for Emcure Pharma

Emcure Pharma is positioned to maintain growth momentum into Q2 FY27 and beyond, supported by order visibility, operational improvements, and sector tailwinds. Management guidance points toward continued expansion in the Pharmaceuticals business with a focus on margin improvement and market share consolidation. Investors tracking Emcure Pharma Q1 FY27 results are advised to consult a SEBI-registered financial advisor before making decisions.

Emcure Pharma Stock Performance After Q1 FY27 Results

Download the Univest iOS App or Univest Android App to track Emcure Pharma live price and get daily stock recommendations.

Emcure Pharma shares were trading lower at Rs 1936.7 (-1.14%) on August 6, 2026, following the declaration of Emcure Pharma Q1 FY27 results. The stock reaction reflects investor sentiment on near-term earnings trajectory and sector outlook. CMP stood at Rs 1936.7 on the results date, with a 52-week range reflecting the broader market sentiment toward the pharmaceuticals sector.

Key Risks for Emcure Pharma

Sector-Specific Headwinds

US FDA regulatory actions, pricing pressure in generics, and USFDA import alerts remain core risks.

Valuation and Earnings Risk

Valuation risk remains if earnings growth fails to sustain at current levels over the next two to three quarters.

Operational and Financial Risk

Subsidiary-level losses or underperformance in overseas operations could drag consolidated PAT lower.

Conclusion

Emcure Pharma Q1 FY27 results demonstrate healthy financial performance with revenue at Rs 2,580 Cr and PAT at Rs 292 Cr on a Consolidated basis. Operating leverage and disciplined cost management will be key drivers for the rest of FY27. Investors should track upcoming management commentary on growth drivers and sector developments before taking positions.

Frequently Asked Questions on Emcure Pharma Q1 FY27 Results

When were Emcure Pharma Q1 FY27 results declared?

Ans. Emcure Pharma Q1 FY27 results were declared on August 6, 2026. The results cover the April to June 2026 quarter on a Consolidated basis.

What was Emcure Pharma revenue in Q1 FY27?

Ans. Emcure Pharma Q1 FY27 results show revenue of Rs 2,580 Cr, +22.85% compared to Rs 2,100 Cr in Q1 FY26.

What was Emcure Pharma PAT in Q1 FY27?

Ans. Net profit (PAT) in Emcure Pharma Q1 FY27 results was Rs 292 Cr, +36.17% year-on-year.

Did Emcure Pharma declare a dividend in Q1 FY27?

Ans. No dividend was declared alongside Emcure Pharma Q1 FY27 results. Investors should check the official company announcements on BSE and NSE for any future dividend declarations.

What is the FY27 outlook for Emcure Pharma?

Ans. Emcure Pharma management has outlined a focus on revenue scaling and margin improvement for the remainder of FY27. Sector tailwinds and order book visibility will be key monitorables.

How did the Emcure Pharma stock react to Q1 FY27 results?

Ans. Emcure Pharma shares were trading lower at Rs 1936.7 (-1.14%) on August 6, 2026, following the Emcure Pharma Q1 FY27 results announcement. Investors should consult a SEBI-registered financial advisor before acting on price movements.